Biocom
BIOCOM AG is a Berlin-based private holding company that makes long-term investments in companies applying biotechnology at industrial scale. With 40 years of operating history, the firm pursues a thematic thesis around the biologization of industry as the next industrial revolution.
- Company typePrivate
- Founded1987
- HeadquartersBerlin, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Biocom does
BIOCOM AG is a Berlin-headquartered Beteiligungsgesellschaft (holding/investment company) that makes long-term investments in companies applying biotechnology at industrial scale. The firm positions itself with 40 years of experience in the sector and frames its thematic mandate as participation in the "Biologisierung der Industrie" (biologization of industry), which it characterizes as the next industrial revolution. Its commercial function is the deployment of capital into industrial-biotech portfolio companies, not the sale of products or services.
The company's externally visible surface is minimal: a corporate website and an active blog are its primary channels, with thought-leadership content authored principally by board member Andreas Mietzsch covering biotechnology regulation, genetic engineering policy, and broader industrial-economic commentary. The BIOCOM® mark is registered and publicly protected. Andreas Mietzsch is the sole disclosed member of the Vorstand (executive board). No portfolio companies, fund vehicles, AUM, headcount, revenue, or transaction history are disclosed in the source material.
Because BIOCOM AG is structured as an Aktiengesellschaft without any stock-exchange listing or ticker, and operates without disclosed investors, subsidiaries, or partnerships, it functions as a private holding entity. Its economic model therefore derives from returns on portfolio investments rather than from conventional product, service, or subscription revenue. Pricing models, customer segments, distribution channels, and product lines are not applicable to the business.
Biocom firmographics
Firmographics- Name
- Biocom
- Legal name
- BIOCOM AG
- Website
- https://biocom.de
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BIOCOM AG is a Berlin-based private holding company that makes long-term investments in companies applying biotechnology at industrial scale. With 40 years of operating history, the firm pursues a thematic thesis around the biologization of industry as the next industrial revolution.
- Ownership category
- akta.pro rank
Biocom industry classification
Industry- Product category
- Investment Holding — Industrial Biotechnology
- NAICS
- Management of Companies and Enterprises (55111)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where Biocom is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Biocom business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Marketing channels1 record
Biocom product offering
Product offeringCore offering
BIOCOM AG is a Beteiligungsgesellschaft (holding/investment company) that makes long-term equity investments in companies applying biotechnology at industrial scale. Leveraging 40 years of sector experience, the firm positions itself around the "biologization of industry" thesis — the view that biotechnology will drive the next industrial revolution — and channels patient capital into industrial-scale biotech operators.
Product overview
BIOCOM AG is a investment holding company (Beteiligungsgesellschaft) with 40 years of experience that makes long-term investments in companies utilizing biotechnology on an industrial scale. The company does not appear to offer a distinct technology product or software platform — rather, it operates as a financial investor in the biotechnology sector. No named product lines, software modules, or SaaS offerings were identified in the source material. The company maintains a blog for news and commentary, but this is a content channel rather than a commercial product.
Differentiator
Problem solved
Functional benefit
Companies that use Biocom
Customer profileIdeal customer profiles1 record
Biocom technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Biocom partnerships and signals
Strategic signalScale indicators1 record
Recent moves1 record
Expansion highlights2 records
Biocom competitors and assessment
Company assessmentDirect peers
- BB Biotech AG: Swiss-domiciled investment company holding a portfolio of biotechnology equities. Like BIOCOM AG, BB Biotech is a publicly structured holding vehicle dedicated exclusively to biotech exposure, making it a direct comparand on mandate and structure.
- Life Sciences Partners (LSP): Amsterdam-based venture and growth capital firm investing across life sciences. LSP is directly comparable to BIOCOM AG as a European life-sciences specialist investor with a long-duration, capital-intensive mandate.
- Seventure Partners: Paris-based growth capital firm with dedicated life-sciences and microbiome/health funds. Comparable to BIOCOM AG as a European specialist investor focused on health and bio-industrial applications of biology.
- Forbion: Dutch life-sciences venture capital firm managing multiple biotech-focused funds. Directly comparable to BIOCOM AG as a European biotech specialist investor operating at scale across the life-sciences value chain.
- Novo Seeds (Novo Holdings): Early-stage life-sciences investment arm of Novo Holdings, investing in biotech and industrial biotech across Europe. Comparable to BIOCOM AG as a specialist, long-duration biotech investor with industrial-bio exposure.
- MIG AG: Munich-based German private equity/venture firm with active life-sciences and biotech exposure. Directly comparable to BIOCOM AG as a German AG-structured investor with a dedicated biotech thesis.
- Wellington Partners: Munich-based venture capital firm with a dedicated life-sciences practice. Comparable to BIOCOM AG as a German/European specialist investor in biotech and industrial life-science applications.
Regional players
- Bioindustrial Innovation Canada (BIC): Canadian organization supporting industrial-biotech and bioeconomy commercialization. Comparable to BIOCOM AG in its focus on industrial-scale biologization, though geographically distinct.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat1 record
Key risks5 records
Key highlights4 records
Customer concentration
Biocom social profiles
Digital presenceBiocom financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biocom leadership team
Management profileNumber of profiles
Profiles1 record
Biocom funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biocom M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biocom
What does Biocom do?
BIOCOM AG is a Beteiligungsgesellschaft (holding/investment company) that makes long-term equity investments in companies applying biotechnology at industrial scale. Leveraging 40 years of sector experience, the firm positions itself around the "biologization of industry" thesis — the view that biotechnology will drive the next industrial revolution — and channels patient capital into industrial-scale biotech operators.
Is Biocom a public or private company?
Biocom is a private company. It is classified as unknown and is currently operating.
When was Biocom founded?
Biocom was founded in 1987. It employs 11 to 50 people.
Where is Biocom based?
Biocom is headquartered in Berlin, Germany, in the Europe region.
Who are Biocom's main competitors?
Direct peers on record are BB Biotech AG, Life Sciences Partners (LSP), Seventure Partners, Forbion, Novo Seeds (Novo Holdings), MIG AG and Wellington Partners. Bioindustrial Innovation Canada (BIC) is listed as a regional player.
Does Biocom have an API?
No public API is recorded for Biocom.
What industry is Biocom in?
Biocom's product category is Investment Holding — Industrial Biotechnology. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 55111.